Minor Cannabinoids as Inhibitors of Skin Inflammation: Chemical Synthesis and Biological Evaluation

Despite millennia of therapeutic plant use, deliberate exploitation of Cannabis’s diverse biomedical potential has only recently gained attention. Bioactivity studies focus mainly on cannabidiol (CBD) and tetrahydrocannabinol (THC) with limited information about the broader cannabinome’s “minor phyt...

Full description

Saved in:
Bibliographic Details
Published in:Journal of natural products (Washington, D.C.) Vol. 87; no. 7; pp. 1725 - 1734
Main Authors: Maiocchi, Alice, Fumagalli, Marco, Vismara, Manuel, Blanco, Asja, Ciriello, Umberto, Paladino, Giuseppe, Piazza, Stefano, Martinelli, Giulia, Fasano, Valerio, Dell’Agli, Mario, Passarella, Daniele
Format: Journal Article
Language:English
Published: United States American Chemical Society and American Society of Pharmacognosy 26-07-2024
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite millennia of therapeutic plant use, deliberate exploitation of Cannabis’s diverse biomedical potential has only recently gained attention. Bioactivity studies focus mainly on cannabidiol (CBD) and tetrahydrocannabinol (THC) with limited information about the broader cannabinome’s “minor phytocannabinoids”. In this context, our research targeted the synthesis of minor cannabinoids containing a lateral chain with 3 or 4 carbon atoms, focusing on cannabigerol (CBG) and cannabichromene (CBC) analogues. Using known and innovative strategies, we achieved the synthesis of 11 C3 and C4 analogues, five of which were inhibitors of skin inflammation, with the CBG-C4 ester derivative emerging as the most potent compound.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0163-3864
1520-6025
1520-6025
DOI:10.1021/acs.jnatprod.4c00212